Navigation Links
Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution
Date:2/18/2009

TEMPO™ for Grant Management assists medical affairs departments in deploying comprehensive investigator-initiated research grant management program

Morrisville, N.C. (PRWEB) February 18, 2009 -- Clinipace, a growing clinical research solutions company, today announced that it has been selected by two pharmaceutical firms to deploy its TEMPO™ for Grant Management solution.

Life science firms are highly cognizant of the multiple pressures to be transparent and compliant in their funding of investigator initiated research (IIR), and are turning to Clinipace in increasing numbers to help them better manage this process. Funding this research is a strategic investment, and maximizing return is critical whether in the form of publications, useful data or stronger community relationships.

Funding investigator-initiated research, in the form of grants, has become an important part of the overall clinical development program, for drugs and devices. This research furthers scientific understanding of real-world clinical profile and product utilization, identifies new indications, and augments the medical literature. As a result, medical affairs departments in many life science companies have established centralized IIR grant management functions and processes.

"Clinipace offers the only software management system that enables life science firms to centralize the application and evaluation process across the portfolio, while simultaneously empowering investigators with the tools and know-how to support individual research projects, all within one software platform. This ensures visibility and success for all stakeholders," said Jeff Williams, Chief Executive Officer at Clinipace.

About Clinipace
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% - 50% savings compared to similar service providers.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb2103804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
2. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
3. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
4. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
5. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
6. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
7. Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
8. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
11. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February ... ... to correct pelvic organ prolapse with the latest techniques and the most minimally ... risk for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR ... AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is ... 5000 perioperative nurses in attendance to study the latest evidence-based recommendations and ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ... indicated by the table. By manipulating each pixel, LUT's can change each color range ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ("Avista ... Setzer as Chief Financial Officer (CFO). Mr. Setzer is ... of experience in various roles within growing technology and ... served as the Executive Director of Finance at INC ... Raleigh, NC . Previously, Mr. Setzer served ...
Breaking Medicine Technology: